Dennis J Donohoe

The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularization Therapies Study part II (ARTS II).

Antonio Colombo, Patrick W Serruys, Thierry Lefèvre, 2007, European heart journal.

Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial.

A. Lansky, W. Wijns, M. Vrolix, 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials.

G. Stone, G. Dangas, J. Moses, 2006, Journal of the American College of Cardiology.

Effect of catheter-based iridium-192 gamma brachytherapy on the added risk of restenosis from diabetes mellitus after intervention for in-stent restenosis (subanalysis of the GAMMA I Randomized Trial).

P. Teirstein, J. Moses, M. Leon, 2002, The American journal of cardiology.

Postmarket evaluation of breakthrough technologies.

Mitchell W Krucoff, Carl J Pepine, Robert M Califf, 2008, American heart journal.

Evaluation of a crystalline sirolimus-eluting coronary stent with a bioabsorbable polymer designed for rapid dissolution: two-year outcomes from the DESSOLVE I and II trials.

P. Stella, M. Morice, W. Wijns, 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Adventitial Drug Delivery of Dexamethasone to Improve Primary Patency in the Treatment of Superficial Femoral and Popliteal Artery Disease: 12-Month Results From the DANCE Clinical Trial.

R. D'Agostino, M. Jaff, M. Razavi, 2018, JACC. Cardiovascular interventions.

Drug-Eluting Stents in the Treatment of Intermediate Lesions

G. Stone, G. Dangas, G. Weisz, 2006 .